Abstract:Abstract Background Heart failure (HF) is considered the most fatal complicating sequelae after myocardial infarction (MI). Various types of programmed cell deaths (PCDs), including apoptosis, necroptosis, and ferroptosis, have been documented as the pathological progression following MI. Although novel pharmacologically specific cell death inhibitors of apoptosis, necroptosis, and ferroptosis have been shown to exert cardioprotection against acute MI and reperfusion injury, their beneficial effects have never been investigated in a post-MI-induced HF model. Purpose To investigate the therapeutic efficacy and potential underlying mechanisms of inhibitors of apoptosis, necroptosis, and ferroptosis in post-MI rats. Methods Adult male Wistar rats were assigned to the sham (n = 6) and the MI groups (n = 30) via a permanent LAD occlusion. After 1-week LAD ligation, MI rats were divided into 5 subgroups: 1) vehicle (3% DMSO/day, IP, CON, n = 6), 2) enalapril (10 mg/kg/day, PO, ENA, n = 6), 3) apoptosis inhibitor zVAD-FMK (1 mg/kg/day, IP, zVAD, n = 6), 4) necroptosis inhibitor Necrostatin-1 (1.65 mg/kg/day, IP, Nec-1, n = 6), or 5) ferroptosis inhibitor Ferrostatin-1 (2 mg/kg/day, IP, Fer-1, n = 6) for 4 weeks. Then, echocardiography for LV function was performed, and the hearts were removed to determine pertinent apoptosis, necroptosis, and ferroptosis proteins by immunoblotting assays. Malondialdehyde (MDA) levels for myocardial oxidative stress were quantified. Results Post-MI rats exhibited worsening LV dysfunction, as indicated by a markedly reduced %LV ejection fraction (LVEF) (Fig. 1A). Post-MI rats showed higher MDA levels in cardiac tissue, indicating myocardial oxidative stress (Fig. 1B). Furthermore, post-MI rats had elevated expressions of proteins related to apoptosis (Cleaved caspase3/Caspase 3) and necroptosis (pMLKL/tMLKL), but not ferroptosis (ACSL4/GAPDH) (Fig. 1C-E). As a standard treatment for MI, enalapril reduced not only myocardial oxidative stress, but also apoptosis and necroptosis activation, thereby enhancing %LVEF after MI (Fig 1A-D). Notably, treatment of post-MI rats with the apoptosis inhibitor zVAD-FMK, necroptosis inhibitor Necrostatin-1, and ferroptosis inhibitor Ferroptosin-1 ameliorated LV dysfunction and myocardial oxidative stress upregulation (Fig A-B). Interestingly, treatment with zVAD, Nec-1, and Fer-1 effectively attenuated both myocardial apoptosis and necroptosis activation after MI (Fig 1C-D). Conclusion Post-MI increased myocardial oxidative stress and activated multiple PCDs, including apoptosis and necroptosis but not ferroptosis, thus leading to LV dysfunction. Apoptosis and necroptosis inhibitors effectively mitigated oxidative stress and myocardial death, resulting in improved LV function in post-MI rats. These findings highlight the therapeutic potential of inhibiting apoptosis and necroptosis as promising pharmacological interventions to improve clinical outcomes for post-MI patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether inhibiting programmed cell death (PCD), including apoptosis, necroptosis and ferroptosis, by pharmacological means can improve left ventricular function (LVF) in heart failure (HF) that occurs after myocardial infarction (MI). Specifically, the researchers hope to explore the therapeutic effects and potential mechanisms of specific cell death inhibitors in a heart failure model after myocardial infarction by using these inhibitors. ### Research Background Heart failure is considered one of the most fatal complications after myocardial infarction. After myocardial infarction, multiple types of programmed cell death, such as apoptosis, necroptosis and ferroptosis, have been proven to be involved in the pathological progression. Although previous studies have shown that specific cell death inhibitors can provide cardioprotective effects against acute myocardial infarction and reperfusion injury, the efficacy of these inhibitors in a heart failure model after myocardial infarction has not been fully studied. ### Research Objectives The main objective of the study is to evaluate the therapeutic effects of apoptosis inhibitor (zVAD - FMK), necroptosis inhibitor (Necrostatin - 1) and ferroptosis inhibitor (Ferrostatin - 1) in a rat model after myocardial infarction and to explore their potential mechanisms of action. ### Research Methods - **Animal Model**: Adult male Wistar rats were divided into a sham - operated group (sham, n = 6) and a myocardial infarction group (MI, n = 30). Myocardial infarction was established by permanent ligation of the left anterior descending artery (LAD). - **Group Treatment**: One week later, the rats with myocardial infarction were randomly divided into 5 subgroups and received the following treatments respectively: - Control group (vehicle, 3% DMSO/day, IP, CON, n = 6) - Enalapril (10 mg/kg/day, PO, ENA, n = 6) - Apoptosis inhibitor zVAD - FMK (1 mg/kg/day, IP, zVAD, n = 6) - Necroptosis inhibitor Necrostatin - 1 (1.65 mg/kg/day, IP, Nec - 1, n = 6) - Ferroptosis inhibitor Ferrostatin - 1 (2 mg/kg/day, IP, Fer - 1, n = 6) - **Observation Indicators**: Four weeks later, echocardiography was performed to evaluate left ventricular function, and the expression levels of related apoptosis, necroptosis and ferroptosis proteins were detected by immunoblotting. Meanwhile, the level of malondialdehyde (MDA) in myocardial tissue was measured to evaluate the degree of oxidative stress. ### Research Results - **Changes in Cardiac Function**: Rats with myocardial infarction showed a significant decline in left ventricular function, manifested as a significant decrease in left ventricular ejection fraction (LVEF) (Figure 1A). - **Oxidative Stress**: The level of MDA in the myocardial tissue of rats with myocardial infarction increased, indicating an increase in myocardial oxidative stress (Figure 1B). - **Expression of Cell Death - related Proteins**: The expression levels of apoptosis - related proteins (Cleaved caspase3/Caspase 3) and necroptosis - related proteins (pMLKL/tMLKL) in the myocardial tissue of rats with myocardial infarction increased, while the expression of ferroptosis - related proteins (ACSL4/GAPDH) did not change significantly (Figure 1C - E). - **Effects of Drug Intervention**: Enalapril not only reduced myocardial oxidative stress, but also reduced the activation of apoptosis and necroptosis, thereby increasing LVEF (Figure 1A - D). The apoptosis inhibitor zVAD - FMK, the necroptosis inhibitor Necrostatin - 1 and the ferroptosis inhibitor Ferrostatin - 1 can effectively improve left ventricular function and myocardial oxidative stress (Figure 1A - B), and significantly reduce myocardial apoptosis and necroptosis.

Therapeutic potential of pharmacological inhibition of programmed apoptosis, necroptosis, and ferroptosis in improving left ventricular function in post-myocardial infarction rats

Abstract 9481: Inhibition of Apoptosis and Ferroptosis Signaling Pathways Alleviates Myocardial Ischemia-Reperfusion Injury in Rats Through Modulation of Mitochondrial Function

Short-Term Pretreatment with Atorvastatin Attenuates Left Ventricular Dysfunction, Reduces Infarct Size and Apoptosis in Acute Myocardial Infarction Rats

Effects of high-intensity interval versus continuous moderate‑intensity aerobic exercise on apoptosis, oxidative stress and metabolism of the infarcted myocardium in a rat model.

A Biomimetic Nanocarrier Strategy Targets Ferroptosis and Efferocytosis During Myocardial Infarction

Inhibition of mevalonate pathway prevents ischemia-induced cardiac dysfunction in rats via RhoA-independent signaling pathway

Delayed β1 Adrenergic Receptor Blockade Attenuates Cardiac Oxidative Stress, Remodeling, and Improves Cardiac Function in Post‐Myocardial Infarction

Resveratrol Attenuate Myocardial Injury by Inhibiting Ferroptosis Via Inducing KAT5/GPX4 in Myocardial Infarction

Persistent Ferroptosis Modulates Cardiac Remodeling and M2 Macrophage Polarization, Which Can be Mitigated by Astaxanthin During Myocardial Infarction Recovery

Anti-Ferroptotic Treatment Deteriorates Myocardial Infarction by Inhibiting Angiogenesis and Altering Immune Response

Treatment with a combination of myricitrin and exercise alleviates myocardial infarction in rats via suppressing Nrf2/HO-1 antioxidant pathway

Anti-apoptosis in nonmyocytes and pro-autophagy in cardiomyocytes: two strategies against postinfarction heart failure through regulation of cell death/degeneration

Interventional Effect of Valsartan on Expression of Inducible Camp Early Repressor and Phosphodiesterase 3A in Rats after Myocardial Infarction.

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats

Vitamins C and E attenuate apoptosis, β-adrenergic receptor desensitization, and sarcoplasmic reticular Ca2+ ATPase downregulation after myocardial infarction

Ferroptosis, a Regulated Form of Cell Death, as a Target for the Development of Novel Drugs Preventing Ischemia/Reperfusion of Cardiac Injury, Cardiomyopathy and Stress-Induced Cardiac Injury

AFC1 Compound Attenuated MI/R-Induced Ventricular Remodeling via Inhibiting PDGFR and STAT Pathway

Activation of NADPH Oxidase Mediates Increased Endoplasmic Reticulum Stress and Left Ventricular Remodeling after Myocardial Infarction in Rabbits.

Idebenone attenuates ferroptosis by inhibiting excessive autophagy via the ROS-AMPK-mTOR pathway to preserve cardiac function after myocardial infarction

Moderate-intensity aerobic exercise inhibits cell pyroptosis to improve myocardial ischemia-reperfusion injury

Ironing out the role of Nrf2 in cardiac iron metabolism during myocardial infarction